Zobrazeno 1 - 10
of 174
pro vyhledávání: '"Shani Paluch Shimon"'
Autor:
Peter Dubsky, Christian Jackisch, Seock-Ah Im, Kelly K. Hunt, Chien-Feng Li, Sheila Unger, Shani Paluch-Shimon
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-12 (2024)
Abstract BRCA1 and BRCA2 are tumor suppressor genes that have been linked to inherited susceptibility of breast cancer. Germline BRCA1/2 pathogenic or likely pathogenic variants (gBRCAm) are clinically relevant for treatment selection in breast cance
Externí odkaz:
https://doaj.org/article/4ffce4033b6c4a57816d72b49c6b2fcd
Autor:
Fatima Cardoso, Shani Paluch-Shimon, Eva Schumacher-Wulf, Leonor Matos, Karen Gelmon, Matti S. Aapro, Jyoti Bajpai, Carlos H. Barrios, Jonas Bergh, Elizabeth Bergsten-Nordström, Laura Biganzoli, Maria João Cardoso, Lisa A. Carey, Mariana Chavez-MacGregor, Runcie Chidebe, Javier Cortés, Giuseppe Curigliano, Rebecca A. Dent, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Sandra X. Franco Millan, Jenny Gilchrist, Joseph Gligorov, William J. Gradishar, Renate Haidinger, Nadia Harbeck, Xichun Hu, Ranjit Kaur, Belinda Kiely, Sung-Bae Kim, Smruti Koppikar, Marion J.J. Kuper-Hommel, Frédéric E. Lecouvet, Ginny Mason, Shirley A. Mertz, Volkmar Mueller, Claire Myerson, Silvia Neciosup, Birgitte V. Offersen, Shinji Ohno, Olivia Pagani, Ann H. Partridge, Frédérique Penault-Llorca, Aleix Prat, Hope S. Rugo, Elzbieta Senkus, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Daniel A. Vorobiof, Peter Vuylsteke, Theresa Wiseman, Binghe Xu, Alberto Costa, Larry Norton, Eric P. Winer
Publikováno v:
Breast, Vol 76, Iss , Pp 103756- (2024)
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023, in Lisbon, Portugal), organized by the ABC Globa
Externí odkaz:
https://doaj.org/article/de357938368a491d8c29ea9020d3b42e
Autor:
Shlomit S. Shachar, Michelle Leviov, Rinat Yerushalmi, Karen Drumea, Margarita Tokar, Lior Soussan-Gutman, Avital Bareket-Samish, Amir Sonnenblick, Noa Ben-Baruch, Ella Evron, Einav Nili Gal-Yam, Shani Paluch-Shimon, Gil Bar-Sela, Hadar Goldvaser, Salomon M. Stemmer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It
Externí odkaz:
https://doaj.org/article/3bcf6bdee0c84eafb59930d692223e0a
Autor:
Ofer Rotem, Idit Peretz, Michelle Leviov, Iryna Kuchuk, Amit Itay, Margarita Tokar, Shani Paluch-Shimon, Ofra Maimon, Rinat Yerushalmi, Karen Drumea, Ella Evron, Amir Sonnenblick, Einav Gal-Yam, Hadar Goldvaser, Yosef Samih, Rotem Merose, Avital Bareket-Samish, Lior Soussan-Gutman, Salomon M. Stemmer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract Data on adjuvant chemotherapy (CT) benefit in ER + HER2‒ early-stage breast cancer (EBC) patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the relationships between the RS, adjuvant treatments, and outc
Externí odkaz:
https://doaj.org/article/ee418dc5761c458bb5099fc02f2cafa0
Autor:
Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman
Publikováno v:
Breast, Vol 66, Iss , Pp 145-156 (2022)
Human epidermal growth factor receptor 2 oncogene (HER2-positive) overexpression/amplification occurs in less than 20% of breast cancers and has traditionally been associated with poor prognosis. Development of therapies that target HER2 has signific
Externí odkaz:
https://doaj.org/article/54b99b760e154469b5c8c8eb580c3532
Autor:
Orit Kaidar-Person, Rakefet Yoeli-Ullman, Nir Pillar, Shani Paluch-Shimon, Philip Poortmans, Yaacov R. Lawrence
Publikováno v:
Breast, Vol 62, Iss , Pp 170-178 (2022)
Purpose: Our aim was to determine whether breast cancer survivors are at increased risk of obstetric and maternal complications at time of delivery. Methods: The USA ‘National Inpatient Sample’ database was queried for hospitalizations associated
Externí odkaz:
https://doaj.org/article/7ea0e27a3bdc461a8ec29bbae9fb739c
Autor:
Shani Paluch-Shimon, Patrick Neven, Jens Huober, Irfan Cicin, Matthew P. Goetz, Chikako Shimizu, Chiun-Sheng Huang, Hans Joachim Lueck, Jane Beith, Eriko Tokunaga, Jessica Reyes Contreras, Rosane Oliveira de Sant’Ana, Ran Wei, Ashwin Shahir, Sarah C. Nabinger, Tammy Forrester, Stephen R. D. Johnston, Nadia Harbeck
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Abemaciclib is the first and only cyclin-dependent kinases 4 and 6 inhibitor approved for adjuvant treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), node-positive, and high-risk ear
Externí odkaz:
https://doaj.org/article/9dbf86693a4a460dbf6601907c6ba0ed
Autor:
Matteo Lambertini, Marcello Ceppi, Anne-Sophie Hamy, Olivier Caron, Philip D. Poorvu, Estela Carrasco, Albert Grinshpun, Kevin Punie, Christine Rousset-Jablonski, Alberta Ferrari, Shani Paluch-Shimon, Angela Toss, Claire Senechal, Fabio Puglisi, Katarzyna Pogoda, Jose Alejandro Pérez-Fidalgo, Laura De Marchis, Riccardo Ponzone, Luca Livraghi, Maria Del Pilar Estevez-Diz, Cynthia Villarreal-Garza, Maria Vittoria Dieci, Florian Clatot, Francois P. Duhoux, Rossella Graffeo, Luis Teixeira, Octavi Córdoba, Amir Sonnenblick, Arlindo R. Ferreira, Ann H. Partridge, Antonio Di Meglio, Claire Saule, Fedro A. Peccatori, Marco Bruzzone, Marie Daphne t’Kint de Roodenbeke, Lieveke Ameye, Judith Balmaña, Lucia Del Mastro, Hatem A. Azim
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Young breast cancer (BC) patients carrying a germline BRCA pathogenic variant (mBRCA) have similar outcomes as non-carriers. However, the impact of the type of gene (BRCA1 vs. BRCA2) and hormone receptor status (positive [HR+] vs. negative [
Externí odkaz:
https://doaj.org/article/5b9aa2e66d9e4375afd2cb11e2219b70
Autor:
Rinat Yerushalmi, Adi Pomerantz, Ron Lewin, Shani Paluch-Shimon, Lior Soussan-Gutman, Frederick Baehner, Hillary Voet, Avital Bareket-Samish, Inbal Kedar, Yael Goldberg, Tamar Peretz-Yablonski, Luna Kadouri
Publikováno v:
Cancer Research. 83:P3-05
Background: The RS assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in ER+ HER2-negative early-stage breast cancer (BC). It is offered to pts irrespective of BRCA1/2 status. We compared RS results, single-gene expression and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::560ccac2a8383ae2a799c815d715eeed
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-59
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-59
Autor:
Fatima Cardoso, Dario Trapani, Carmen Criscitiello, Giuseppe Curigliano, Evandro de Azambuja, Sibylle Loibl, Suzette Delaloge, Elzbieta Senkus, Philip Poortman, Michael Gnant, Serena Di Cosimo, Javier Cortes, Shani Paluch-Shimon
Publikováno v:
ESMO Open, Vol 5, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/b441eac5f95b4ba2bca7de34a28354ac